This Article Full Text (PDF) References Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Add to Saved Citations Download to citation manager Request Permissions Request Reprints Add to My Marked Citations Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Citing Articles via Scopus Google Scholar Articles by Watts, C. Articles by Whurr, R. Search for Related Content PubMed PubMed Citation Articles by Watts, C. Articles by Whurr, R. Pubmed/NCBI databases Substance via MeSH Medline Plus Health Information Voice Disorders Social Bookmarking                         What's this?

Botulinum toxin for treating spasmodic dysphonia (laryngeal dystonia): a systematic Cochrane review

James Madison University, Harrisonburg, VA

Chad Nye

University of Central Florida, Orlando, FL, USA

Renata Whurr

National Hospital for Neurology and Neurosurgery, London, UK

Background: Spasmodic dysphonia is a neurological voice disorder characterized by involuntary adductor (towards midline) or abductor (away from midline) vocal fold spasms during phonation which result in phonatory breaks. Botulinum toxin is currently the gold standard of treatment.

Objective: To determine the efficacy of botulinum toxin therapy for the treatment of spasmodic dysphonia.

Design: Systematic Cochrane review.

Search strategy: The search strategy for this review complied with Cochrane standards. We searched the Cochrane Central Register of Controlled Trials (CENTRAL), MEDLINE (1966 to February 2005), EMBASE (1974 to February 2005), CINAHL (through February 2005), Dissertation Abstracts International (1975 to February 2005) and PsycINFO (1975 to February 2005). The search engine FirstSearch was also used (February 2005). Reference lists for all the obtained studies and other review articles were examined for additional studies.

Selection criteria: All randomized control trials where the participants were randomly allocated prior to intervention and in which botulinum toxin was compared to an alternative treatment, placebo or non-treated control group were included.

Data collection and analysis: Two reviewers independently evaluated all potential studies meeting the selection criteria noted above for inclusion.

Main results: Only one study in the literature met the inclusion criteria. This was the only study identified which reported a treatment/no treatment comparison. It reported significant beneficial effects for fundamental frequency (Fo), Fo range, spectrographic analysis, independent ratings of voice severity and patient ratings of voice improvement.

Reviewer's conclusions: The evidence from randomized controlled trials supporting the effectiveness of botulinum toxin for management of spasmodic dysphonia is deficient. The lack of supporting evidence from randomized controlled trials results in an inability to draw unbiased generalized conclusions regarding the effectiveness of botulinum toxin for all types of spasmodic dysphonia.

Clinical Rehabilitation, Vol. 20, No. 2, 112-122 (2006)
DOI: 10.1191/0269215506cr931oa


CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter    What's this?

This article has been cited by other articles:

				T. Isken, A. Gunlemez, B. Kara, H. Izmirli, and H. Gercek Botulinum Toxin for the Correction of Asymmetric Crying Facies Aesthetic Surgery Journal, November 1, 2009; 29(6): 524 - 527. [Abstract] [Full Text] [PDF]